SEPHIENCE Drug Patent Profile

When do Sephience patents expire, and when can generic versions of Sephience launch?

Sephience is a drug marketed by Ptc Therap and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-five patent family members in thirteen countries.

The generic ingredient in SEPHIENCE is sepiapterin. Two suppliers are listed for this compound. Additional details are available on the sepiapterin profile page.

DrugPatentWatch^® Generic Entry Outlook for Sephience

Sephience will be eligible for patent challenges on July 28, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 28, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SEPHIENCE

International Patents:	55
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
What excipients (inactive ingredients) are in SEPHIENCE?	SEPHIENCE excipients list
DailyMed Link:	SEPHIENCE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SEPHIENCE

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

219666

Dosage:

POWDER;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SEPHIENCE

SEPHIENCE is protected by four US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ptc Therap	SEPHIENCE	sepiapterin	POWDER;ORAL	219666-002	Jul 28, 2025		RX	Yes	Yes
Ptc Therap	SEPHIENCE	sepiapterin	POWDER;ORAL	219666-001	Jul 28, 2025		RX	Yes	No
Ptc Therap	SEPHIENCE	sepiapterin	POWDER;ORAL	219666-002	Jul 28, 2025		RX	Yes	Yes				Y
Ptc Therap	SEPHIENCE	sepiapterin	POWDER;ORAL	219666-001	Jul 28, 2025		RX	Yes	No			Y
Ptc Therap	SEPHIENCE	sepiapterin	POWDER;ORAL	219666-002	Jul 28, 2025		RX	Yes	Yes
Ptc Therap	SEPHIENCE	sepiapterin	POWDER;ORAL	219666-002	Jul 28, 2025		RX	Yes	Yes			Y
Ptc Therap	SEPHIENCE	sepiapterin	POWDER;ORAL	219666-001	Jul 28, 2025		RX	Yes	No

International Patents for SEPHIENCE

See the table below for patents covering SEPHIENCE around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	391156
European Patent Office	3548497
Japan	2023116556	セピアプテリンを含む医薬組成物及びその使用 (PHARMACEUTICAL COMPOSITIONS COMPRISING SEPIAPTERIN AND USES THEREOF)
World Intellectual Property Organization (WIPO)	2018102314
China	116903624
Mexico	2019006206
South Korea	102561697

SEPHIENCE Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for SEPHIENCE?

SEPHIENCE (elotuzumab), an immunotherapy drug developed by Bristol Myers Squibb (BMS), targets relapsed or refractory multiple myeloma. Market dynamics are shaped by its clinical application, competition, regulatory environment, and pricing strategy.

Clinical Positioning and Therapeutic Use

SEPHIENCE addresses relapsed or refractory multiple myeloma in patients who have received at least one prior therapy. It functions as part of combination regimens, including with lenalidomide and dexamethasone. The drug's mechanism involves activating natural killer (NK) cells, which distinguishes it from other monoclonal antibodies.

Competitive Landscape

The multiple myeloma market features several marketed therapies, including:

• Darzalex (daratumumab) by Janssen
• Empliciti (elotuzumab) by BMS
• Reblozyl (luspatercept) by BMS (for anemia)
• Black box warnings exist for some competitors concerning infusion reactions and hematologic toxicities.

SEPHIENCE faces competition from these agents, particularly from daratumumab, which has a broader label and higher uptake. The market is also expanding toward multi-therapy regimens that combine agents for synergistic efficacy.

Regulatory and Reimbursement Factors

SEPHIENCE was approved by the Food and Drug Administration (FDA) in 2015. It received approval based on clinical trials demonstrating improvements in progression-free survival (PFS), but it lacks an overall survival (OS) benefit claim.

Reimbursement depends on approved indications, competitive pricing, and payer policies. In the U.S., reimbursement for multiple myeloma treatments is affected by coverage determinations, especially where competing drugs are preferred.

Market Penetration and Adoption

SEPHIENCE's initial adoption was limited due to being a second-line therapy and competition from more established agents. Its use has increased modestly with the expansion of combination regimens and updates to clinical guidelines favoring immunotherapy approaches.

Pricing and Revenue Considerations

Pricing for monoclonal antibodies in multiple myeloma ranges from $75,000 to $100,000 annually per patient. SEPHIENCE's price is similar to competitors but has faced pressure for value-based reimbursement and biosimilar competition, though biosimilars for monoclonal antibodies targeting CD2 and other markers are limited.

What Is the Financial Trajectory for SEPHIENCE?

Revenue Trends and Sales Data

Sales of SEPHIENCE peaked around 2017-2018 due to initial market penetration, then plateaued as competitors gained market share. BMS reported domestic sales of approximately $150 million in 2020, with global sales estimated at $200 million. The drug's revenue growth has been modest due to:

• Limited use in third-line settings
• Competition from newer therapies
• Limited overall patient population eligible for its use

Key Factors Affecting Financial Performance

• Market approval scope: FDA approval limited to relapsed/refractory multiple myeloma limits market size.
• Off-label use: No significant off-label prescribing reported, constraining revenue.
• Pipeline developments: Ongoing trials exploring expanded indications could impact long-term revenue.
• Biosimilar threat: As biosimilars become available, prices may decline.

Future Revenue Opportunities

Potential growth depends on:

• Expansion into earlier lines of therapy
• Combination regimens demonstrating improved outcomes
• Label expansion for other hematologic malignancies

However, as competitors develop and biosimilars emerge, revenue growth may plateau or decline unless SEPHIENCE gains differentiated clinical positioning.

Investment and R&D Outlook

BMS continues to develop combination regimens involving SEPHIENCE and explores new indications. Clinical trials investigating efficacy in solid tumors and other hematological cancers could broaden the drug's application and revenue streams eventually.

Key Takeaways

• SEPHIENCE faces stiff competition from daratumumab and other monoclonal antibodies in multiple myeloma.
• Its market share is limited by existing second-line therapies, with modest revenue contributions.
• Pricing is comparable to similar monoclonal antibodies, but biosimilar competition could threaten margins.
• Long-term growth depends on expanding indications and demonstrating clinical advantages over competitors.
• Current sales are steady but face challenges from biosimilars and evolving treatment standards.

FAQs

1. When was SEPHIENCE approved?
FDA approved SEPHIENCE in 2015 for relapsed/refractory multiple myeloma.

2. What is the primary mechanism of action?
It activates natural killer cells, which target and destroy myeloma cells.

3. Who are the main competitors?
Daratumumab (Darzalex) by Janssen is the leading competitor, with others like Empliciti (elotuzumab) by BMS.

4. Can SEPHIENCE be used in first-line treatment?
No, current approval limits its use to relapsed or refractory cases after at least one prior therapy.

5. What threats could impact its revenue?
Biosimilar entries, evolving treatment standards, and the emergence of more effective combination therapies.

---

References

[1] Bristol Myers Squibb, "SEPHIENCE (elotuzumab) Prescribing Information," 2015.
[2] IQVIA, "Global Oncology Market Reports," 2021.
[3] FDA.gov, "Drug Approvals and Labeling," 2015.
[4] EvaluatePharma, "Market Trends in Multiple Myeloma," 2022.
[5] MarketWatch, "Biosimilar Competition in Oncology," 2022.